| 题名 | 中国药理学报（英文版） |
| 作者 | |
| 发表日期 | 2020
|
| 发表期刊 | |
| ISSN | 1671-4083
|
| 卷号 | 41期号:3页码:394-403 |
| 摘要 | RNF6,a RING-type ubiquitin ligase,has been identified as an oncogene in various cancers but its role in multiple myeloma (MM) remains elusive.In the present study we first showed that the expression levels of RNF6 in MM were significantly elevated compared with the bone marrow cells of healthy donors.Overexpression of RNF6 in LP1 and PRMI-8266 MM cell lines promoted cell proliferation,whereas knockdown of RNF6 led to apoptosis of MM cells.Furthermore,we revealed that RNF6,as a ubiquitin ligase,interacted with glucocorticoid receptor (GR) and induced its K63-linked polyubiquitination.Different from current knowledge,RNF6 increased GR stability at both endogenous and exogenous contexts.Such an action greatly promoted GR transcriptional activity,which was confirmed by luciferase assays and by the increased expression levels of prosurvival genes including Bcl-xL and Mcl-1,two typical downstream genes of the GR pathway.Consistent with these findings,ectopic expression of RNF6 in MM cells conferred resistance to dexamethasone,a typical anti-myeloma agent.In conclusion,we demonstrate that RNF6 promotes MM cell proliferation and survival by inducing atypical polyubiquitination to GR,and RNF6 could be a promising therapeutic target for the treatment of MM. |
| 关键词 | |
| 相关链接 | [万方记录] |
| 语种 | 英语
|
| 学校署名 | 其他
|
| 资助项目 | (This work was supported by the National Natural Science Foundation of China )%(the Natural Science Foundation of Jiangsu Higher Education Institutes of China )%(Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province )%(The Jiangsu Provinicial Medical Talent )%and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
|
| ESI学科分类 | PHARMACOLOGY & TOXICOLOGY
|
| 来源库 | WanFang
|
| 万方记录号 | perioarticalzgylxb202003011
|
| 成果类型 | 期刊论文 |
| 条目标识符 | http://sustech.caswiz.com/handle/2SGJ60CL/229202 |
| 专题 | 南方科技大学医学院 |
| 作者单位 | 1.Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China 2.School of Medicine, South University of Science and Technology, Shenzhen 518055, China 3.Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore 4.National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215100, China 5.Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China;National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215100, China;protein Modification and Degradation Key Lab of Guangzhou and Guangdong, School of Basic Medical Sciences, Affiliated Cancer Hos 6.苏州大学 7.南方科技大学 8.新加坡国立大学 9.苏州大学附属第一医院 10.苏州市第一人民医院；苏州大学附属第一医院 |
| 推荐引用方式 GB/T 7714 |
Ying Ren,Xin Xu,Chen-yu Mao,等. 中国药理学报（英文版）[J]. ACTA PHARMACOLOGICA SINICA,2020,41(3):394-403.
|
| APA |
Ying Ren.,Xin Xu.,Chen-yu Mao.,Kun-kun Han.,Yu-jia Xu.,...&Xin-liang Mao.(2020).中国药理学报（英文版）.ACTA PHARMACOLOGICA SINICA,41(3),394-403.
|
| MLA |
Ying Ren,et al."中国药理学报（英文版）".ACTA PHARMACOLOGICA SINICA 41.3(2020):394-403.
|
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论